Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2012 pubmed 26 citations

Alveolar macrophage cathelicidin deficiency in severe sarcoidosis.

Barna. Barbara P BP; Culver. Daniel A DA; Kanchwala. Ali A; Singh. Ravinder J RJ; Huizar. Isham I; Abraham. Susamma S; Malur. Anagha A; Marshall. Irene I; Kavuru. Mani S MS; Thomassen. Mary Jane MJ

Key Findings

  • Severe sarcoidosis patients show reduced LL‑37 and SRC3 expression in lung macrophages
  • Normal vitamin D3 levels do not restore LL‑37 when TNF‑α is high
  • TNF‑α directly suppresses both SRC3 and LL‑37 production in vitro

Practical Outcomes

  • For biohackers, the take‑away is that simply boosting vitamin D3 may not raise LL‑37 if chronic inflammation (high TNF‑α) is present. Strategies that lower systemic inflammation or directly supplement LL‑37 (if available) could be more effective for enhancing this peptide’s benefits.

Summary

The study found that people with severe sarcoidosis have lower levels of the immune‑boosting peptide LL‑37 in their lung cells, even though their active vitamin D3 levels are normal. This drop is linked to high inflammation signals (TNF‑α) that suppress a helper protein (SRC3) needed for LL‑37 production. In simpler terms, inflammation can block the body’s natural production of this antimicrobial peptide despite adequate vitamin D.

Abstract

Dysfunctional immune responses characterize sarcoidosis, but the status of cathelicidin, a potent immunoregulatory and antimicrobial molecule, has not been established in clinical disease activity. Alveolar macrophage cathelicidin expression was determined in biopsy-proven sarcoidosis patients classified clinically as 'severe' (requiring systemic treatment) or 'non-severe' (never requiring treatment). Bronchoalveolar lavage (BAL) cells from sarcoidosis patients and healthy controls were analyzed for mRNA expression of cathelicidin, vitamin D receptor (VDR) and the VDR coactivator steroid receptor coactivator-3 (SRC3) by quantitative PCR. Cathelicidin-derived peptide LL-37 was determined by immunocytochemistry. Serum calcidiol (25-hydroxyvitamin D2; vitD2) and calcitriol (1,25-dihydroxyvitamin D3; vitD3) were quantified. The results indicated reduced BAL cell expression of cathelicidin and SRC3 in severe but not non-severe sarcoidosis compared to controls. Serum levels of biologically active vitD3 in both severe and non-severe patients were within the control range even though vitD2 levels in both groups were below the recommended level (30 ng/ml). Sarcoidosis and control alveolar macrophages were studied in vitro to determine cathelicidin responses to vitD3 and tumor necrosis factor-α (TNFα), a vitD3 antagonist elevated in active sarcoidosis. Alveolar macrophage cathelicidin was stimulated by vitD3 but repressed by TNFα, which also repressed SRC3. These findings suggest that TNFα-mediated repression of SRC3 contributes to alveolar macrophage cathelicidin deficiency in severe sarcoidosis despite healthy vitD3 levels. Deficiency of cathelicidin, a multifunctional regulator of immune cells and proinflammatory cytokines, may impede resolution of inflammation in the lungs of patients with severe sarcoidosis.

Study Information

Provider

pubmed

Year

2012

Date

2012-07-03T00:00:00.000Z

DOI

10.1159/000339149

Citations

26

References

46